Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "Ibrutinib"

EMA recommends eight drugs for approval

Pending EC decision: Imbruvica, ibrutinib, Opinion date: 21-M...

the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Imbruvica. The marketing authorisation holder for this medicinal product ... European Medicines Agency, 1 day ago

3 images for "Ibrutinib"

MDLinx, 2 days ago
OncLive, 3 weeks ago, 1 month ago

Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA(R) (Ibrutinib) for the Treatment of WaldenstrAm's Macroglobulinemia

/PRNewswire/ -- A rare B-cell lymphoma with no EMA-approved treatment options available Janssen-Cilag International NV (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
 Individual.com1 day ago Janssen erhält positive Stellungnahme des CHMP, das IMBRUVICA® (Ibrutinib) zur Behandlung von Morbus Waldenström empfiehlt  BioMedReports1 day ago 'New Era' in the Treatment of Rare Lymphoma  General Medicine eJournal1 month ago

[News] Ibrutinib in pretreated Waldenström's macroglobulinaemia

New research suggests that ibrutinib—an inhibitor of Bruton's tyrosine kinase—has substantial activity and is safe for use in previously treated patients with
 Lancet Neurology3 weeks ago Findings in Waldenstrom Macroglobulinemia Reported from Pharmacyclics (Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia)  4 Traders3 weeks ago Ibrutinib Gets High Marks for Waldenstrom's Macroglobulinemia  MedPage Today1 month ago Ibrutinib safe, effective in previously treated Waldenström's macroglobulinemia  Orthopedics Today1 month ago

Human medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Revision: 1, Authorised

This is a summary of the European public assessment report (EPAR) for Imbruvica. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago
Science Daily

New Waldenstrom's drug shows sustained benefit at two years

( Dana-Farber Cancer Institute ) Dana-Farber researchers report in the New England Journal of Medicine that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients ...
 Infrosoft1 month ago New Waldenström's drug shows sustained benefit at two years  OncologyNurse.com1 month ago News and press releases: First medicine for rare blood cancer  European Medicines Agency1 day ago Newly approved drug for rare blood cancer shows sustained benefit for 2 years  News-Medical.Net1 month ago

Phase 3 Study with IMBRUVICA® (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression

/PRNewswire/ --Janssen Research & Development, LLC (Janssen) announced today that a pre-planned interim analysis of the Phase 3 HELIOS (CLL3001) study investigating the combination of IMBRUVICA ® (ibrutinib) plus bendamustine and rituximab (BR) ...
 RCL Advisors2 months ago Phase 3 Study with IMBRUVICA (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression  FirstWord Pharma2 months ago Phase 3 Study with IMBRUVICA?? (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression  Tutorial Finder2 months ago Phase 3 Study with IMBRUVICA(r) (ibrutinib) Combination Demonstrates  Finwin2 months ago

TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 51st Annual Meeting of the American Society of Clinical Oncology

The Triple-Combination Therapy of TG-1101, TGR-1202, and ibrutinib to be Highlighted in an Oral Presentation Updates on the Combination of TG-1101 Plus TGR-1202, and Single-Agent TGR-1202 to be Featured in Poster Presentations NEW YORK, May ...
 Industrial Info Financials1 week ago Ligand Reports First Quarter 2015 Financial Results Business Wire  Yahoo! Finance1 week ago Ligand Pharmaceuticals : Reports First Quarter 2015 Financial Results  4 Traders1 week ago A Comprehensive Look At AbbVie's Competition Against Its Top 10 Products  Seeking Alpha2 weeks ago

Janssen reçoit un avis favorable de la part du CHMP à la recommandation d'IMBRUVICA® (Ibrutinib) pour le traitement de la macroglobulinémie de Waldenström

IMBRUVICA is already approved in Europe for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first ...
 BioMedReports1 day ago

Janssen recibe comentarios positivos del CHMP al recomendar IMBRUVICA® (Ibrutinib) para el tratamiento de la macroglobulinemia de Waldenström

 BioMedReports1 day ago

Forum Post: RE: Ibrutinib

Hi Sharrie. Haven't had Ibrutinib so cant comment. Have you have a stem cell transplant? I have, so maybe drugs are different for different forms of treatment. If you dont get a response from this page (not too many MCL folk) you may get more ...
 Macmillan Cancer Support2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
Get updated on latest news & your favorite topics right in your inbox!
More     Less